✦ LIBER ✦

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

✍ Scribed by Elmar A Joura; Sepp Leodolter; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Laura A Koutsky; Suzanne M Garland; Diane M Harper; Grace WK Tang; Daron G Ferris; Marc Steben; Ronald W Jones; Janine Bryan; Frank J Taddeo; Oliver M Bautista; Mark T Esser; Heather L Sings; Micki Nelson; John W Boslego; Carlos Sattler; Eliav Barr; Jorma Paavonen

Book ID: 117301193
Publisher: The Lancet
Year: 2007
Tongue: English
Weight: 165 KB
Volume: 369
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(07)60777-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prophylactic quadrivalent human papillom

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

✍ Luisa L Villa; Ronaldo LR Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 109 KB

Effect of prophylactic human papillomavi

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

✍ Kevin A. Ault 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 133 KB

Efficacy of a prophylactic adjuvanted bi

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

✍ Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Coset 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 151 KB

Sustained efficacy up to 4·5 years of a

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

Sustained efficacy up to 4·5 years of a

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

## Background: Effective vaccination against hpv 16 and hpv 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent hpv-16/18 l1 virus-like part

Efficacy of a bivalent L1 virus-like par

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

✍ Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 185 KB